cbdMD, Inc. (YCBD) cbdMD, Inc. is engaged in the production and distribution of a diverse array of cannabidiol (CBD) products. The company oversees and markets several consumer-oriented, hemp-derived CBD brands, notably its primary brand cbdMD, alongside Paw CBD and cbdMD Botanicals. Under the cbdMD label, its offerings span various items, including CBD tinctures, edible gummies, topical applications, capsules, bath bombs, bath salts, and solutions designed to aid sleep. Furthermore, its Paw CBD brand caters to pets with veterinarian-formulated products such as tinctures, edible chews, and topical treatments. The company's merchandise reaches customers throughout the United States via its proprietary e-commerce platform, various third-party online retail sites, wholesale partners, and physical brick-and-mortar establishments. cbdMD, Inc. also maintains a research collaboration with the University of Mississippi, focusing on the discovery of novel cannabinoids. Incorporated in 2015, the firm was previously known as Level Brands, Inc. before officially changing its name to cbdMD, Inc. in May 2019, and its corporate headquarters are situated in Charlotte, North Carolina.
Sector: Perfumes, Cosmetics & Other Toilet Preparations
Industry: Drug Manufacturers - Specialty & Generic
cbdMD, Inc. NYSE:YCBD Healthcare · Drug Manufacturers - Specialty & Generic
AH Close $0.3648 +0.00% vs close
AH Close $0.3648 +0.00% vs close
All Press Release SEC Filings News
Press Release ⚠ 1
Reserveage Launches Longev+ Exclusively at The Vitamin Shoppe, Bringing Strength Into the Healthy Aging Conversation
Reserveage, part of the Twinlab family of brands, launched Longev+, a healthy-aging supplement combining amino acids, HMB, creatine and resveratrol, available exclusively at The Vitamin Shoppe in a 20-count Mixed Berry stick-pack format.
The launch is relevant to cbdMD (YCBD) because Reserveage is among the Twinlab brands included in cbdMD's previously announced definitive asset purchase agreement, which remains subject to court approval and customary closing conditions.
For YCBD the event is indirect: it supports the strategic rationale cited by cbdMD management for the Twinlab deal, but no financial figures or deal terms were disclosed in the release.
• 1mo ago AI analysis › News
cbdMD (NYSEAMERICAN:YCBD) Trading Up 5.1% – What’s Next?
defenseworld.net • 1mo ago Press Release ● Critical ⚠ 4
cbdMD Enters Definitive Agreement to Acquire Twinlab Brands, Expanding Into Legacy Supplements, Sports Nutrition, Women's Beauty, Weight Loss and Longevity Wellness
cbdMD (NYSE American: YCBD) has signed a definitive asset purchase agreement to acquire the operating assets and brands of Twinlab — including Twinlab, Reserveage, Metabolife, and Alvita Tea — through an assignment for the benefit of creditors proceeding that remains subject to court approval and customary closing conditions.
Based on unaudited figures, combined trailing-twelve-month revenue through June 2026 totals approximately $30 million, roughly 40% above cbdMD's standalone revenue for the same period, with the incremental revenue expected to generate positive contribution after transaction and integration costs.
Management frames the deal as diversifying away from hemp-derived CBD concentration and its associated regulatory risk, extending the multi-brand wellness platform strategy it began with the Bluebird Botanicals acquisition.
The acquired brands bring distribution across roughly 50,000 retail outlets including Vitamin Shop and GNC plus a strong Amazon presence; key risks include an undisclosed purchase price, court approval of the ABC process, and reliance on unaudited target financials.
• 1mo ago AI analysis › News
cbdMD, Inc. (YCBD) Q3 2026 Earnings Call Transcript
seekingalpha.com • 2mo ago Press Release ● Major
cbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026
prnewswire.com • 2mo ago SEC Filing ● Major ⚠ 8
YCBD: 10-Q · periodic report
cbdMD reported fiscal Q3 2026 net sales of $5.6 million, up 20% year over year, with nine-month net sales of $16.2 million, up 12%, but the net loss widened to $2.2 million for the nine months from $1.4 million a year earlier as gross margin fell roughly 6 points on wholesale mix shift and a $187,437 inventory reserve build.
The company disclosed substantial doubt about its ability to continue as a going concern, holding $2.1 million of cash against a $181.8 million accumulated deficit, and is leaning on a $20 million equity line of credit with C/M Capital Master Fund, LP that has so far produced only a $61,990 draw.
The larger overhang is regulatory: Section 781 of H.R. 5371, scheduled to take effect November 12, 2026, would cap hemp-derived THC at 0.4 mg per container, and management states the Act as written will likely have a material adverse impact since only 61% of nine-month revenue came from products that would comply. The FDA also completed a GMP inspection of the Charlotte facility with documentation and quality-control observations, though no product safety issues were identified.
Offsetting actions include a cost program targeting $1.2-$1.8 million in annualized savings beginning fiscal Q4 2026 and the Bluebird Botanicals acquisition, which added over $550,000 of quarterly revenue; the company is also expanding into Kava and non-THC products to hedge the legislative risk.
SEC 10-Q • 2mo ago AI analysis › Press Release
cbdMD, Inc. to Host Conference Call to Discuss June 30, 2026, Third Quarter Results
cbdMD announced it will host a conference call on August 13, 2026, at 4:20 p.m. ET to discuss its third quarter financial results for the period ended June 30, 2026.
The call will cover business progress and financial performance; interested parties can access the event via a live webcast or by dialing in.
Ronan Kennedy, the company's CEO and CFO, is listed as the primary contact for investor inquiries.
• 2mo ago AI analysis › Press Release
cbdMD Applauds Proposed SENATE SPENDING BILL That Would Protect Access to Full-Spectrum CBD and Other Naturally Derived Hemp Products
prnewswire.com • 2mo ago Press Release
cbdMD Supports the Bipartisan Lawful Hemp Protection Act to Protect Consumers and Full-Spectrum CBD Access
prnewswire.com • 3mo ago Press Release
cbdMD's Oasis Brand Partners with Mexcor to Launch Into South Carolina
cbdMD announced a distribution agreement with Morales Beverage Group to launch its Oasis hemp-derived beverage line in South Carolina.
The statewide rollout includes the full Oasis portfolio, featuring the new zero-proof Mixer, placing products on shelves at retailers like Frugal MacDoogal.
Management emphasized that placement in established liquor channels alongside traditional alcohol will help introduce the brand to a broader adult audience.
• 3mo ago AI analysis › Press Release
cbdMD's Bluebird Botanicals Announces Official Partnership With Denver Audubon to Support Bird Conservation
cbdMD announced a partnership between its Bluebird Botanicals brand and Denver Audubon to support bird conservation in Colorado.
The initiative includes a "Buy Bluebird, Save Bluebirds" campaign where Bluebird will donate 1% of profits from product sales over three months this summer.
CEO Ronan Kennedy stated the partnership reinforces the brand's commitment to nature, transparency, and responsible wellness following its acquisition by cbdMD.
• 3mo ago AI analysis › Press Release
cbdMD Sets a New Safety Standard for Broad Spectrum CBD With Self-Affirmed GRAS Determination
cbdMD announced a self-affirmed GRAS determination for its broad spectrum CBD, supporting the safe consumption of up to 200 mg per day for healthy adults.
The determination was made by an independent panel of expert toxicologists following a review of years of peer-reviewed safety research conducted by the company.
This milestone allows cbdMD to pursue expansion into healthcare channels and aligns with recent CMS and FDA initiatives regarding hemp-derived products.
• 3mo ago AI analysis › Press Release ⚠ 1
Oasis Launches Hemp-Derived Mixer
cbdMD's Herbal Oasis brand launched Oasis Mixer, a zero-proof, quad-filtered THC spirit designed to mix into beverages without clouding them.
The product features 10mg THC per serving (170mg per bottle), zero calories or sugar, and a resealable child-resistant cap for regulatory compliance.
Initial production run was over-subscribed by distributors, with availability rolling out in Tennessee, Florida, Texas, South Carolina, and select North Carolina markets.
• 3mo ago AI analysis › Press Release ⚠ 2
cbdMD Welcomes White House Call for Fair Treatment of Hemp-Derived Products
cbdMD welcomed a letter from the White House Office of Management and Budget urging Congress to ensure fair treatment of hemp-derived products and prioritize hemp reform.
The Administration called for preserving access to full-spectrum CBD while restricting harmful products, and urged either a responsible federal framework or an extension of the implementation timeline.
CEO Ronan Kennedy emphasized cbdMD's position as an established, NYSE American-listed company, noting that recent moves by exchanges to list compliant operators signal increasing market maturity.
• 4mo ago AI analysis › Press Release
cbdMD Appoints Wade Brown Chief Marketing Officer
cbdMD promoted Wade Brown to Chief Marketing Officer, formalizing a role he has effectively held since joining the company in March 2025 to stabilize its brand portfolio.
The company reported 19% year-over-year and 12% sequential revenue growth, supported by momentum in its core brands and the integration of Bluebird Botanicals.
Brown will now oversee marketing and commercial growth across cbdMD's multi-brand portfolio, which includes cbdMD, Paw CBD, Oasis, and Bluebird Botanicals.
• 4mo ago AI analysis › SEC Filing
YCBD: 8-K · material agreement
cbdMD, Inc. entered into a Third Amendment to its warehouse and executive office lease in Charlotte, NC, reducing its occupied space from 80,000 to 40,000 square feet. The amendment extends the lease term by 62 months, with a new expiration date of November 30, 2031, and includes a two-month rent abatement period starting October 1, 2026.
The company expects the lease reduction to lower its gross rent expense by approximately $450,000 per year. After accounting for ongoing sublet rent, management estimates a net annual rent expense reduction of $100,000 to $120,000, aligning the facility footprint with current operational needs.
SEC 8-K • 5mo ago AI analysis › News
cbdMD, Inc. (YCBD) Q2 2026 Earnings Call Transcript
seekingalpha.com • 5mo ago Press Release ⚠ 3
cbdMD Reports 19% Year-over-Year and 12% Sequential Revenue Growth; Bluebird Acquisition Integration and Medicare BEI Pathway Position Company for Continued Momentum
cbdMD reported Q2 FY26 revenue of $5.6 million, a 19% increase year-over-year and 12% sequentially, driven by core business growth and the integration of Bluebird Botanicals.
The company posted a net loss of $0.88 million ($0.08 per share) and an adjusted EBITDA loss of $220,000, though operating losses narrowed compared to the prior year period when excluding acquisition costs.
Management highlighted the activation of the CMS Medicare BEI pathway as a key catalyst, allowing eligible participants to furnish hemp-derived CBD products to beneficiaries, positioning cbdMD as an evidence-based supplier in the clinical healthcare channel.
• 5mo ago AI analysis › SEC Filing ● Major ⚠ 6
YCBD: 10-Q · periodic report
cbdMD, Inc. reported a net loss of $1.1 million for the six months ended March 31, 2026, alongside a critical going-concern warning stating there is 'substantial doubt' about its ability to continue as a going concern within twelve months. The company holds only $2.6 million in cash against an accumulated deficit of $180.6 million, relying on a newly established $20 million equity line of credit (ELOC) and preferred stock financing to maintain liquidity.
Revenue grew 8% year-over-year to $10.7 million, driven by a 19% sequential increase in the quarter and the January 2026 acquisition of Bluebird Botanicals for $937,000 in stock. However, operating expenses rose 17% to $4.1 million in the quarter, pressured by integration costs, regulatory rework, and increased marketing spend, resulting in a widening operating loss.
The filing highlights severe regulatory headwinds, specifically H.R. 5371, which narrows the federal definition of hemp and could materially adversely impact the company’s THC-containing product lines. Additionally, the company completed a 1-for-8 reverse stock split in May 2025 and faces significant dilution from the conversion of Series B and C Preferred Stock, which accrue 10% annual dividends payable in cash or stock.
SEC 10-Q • 5mo ago AI analysis › Press Release
cbdMD, Inc. to Host Conference Call to Discuss March 31, 2026, Second Quarter Results
cbdMD, Inc. will host a conference call on May 14, 2026, at 4:20 p.m. Eastern Time to discuss its second quarter financial results and business progress.
The company is one of the leading and most trusted CBD brands, offering a comprehensive line of THC-free CBD products and an array of Delta 9 products.
cbdMD also operates the Paw CBD brand for pets, the ATRx brand for functional mushrooms, and Herbal Oasis, a THC-infused social seltzer.
• 5mo ago AI analysis › Press Release
cbdMD Launches Clinical Healthcare Channel to Support First Federal Pathway for Hemp-Derived CBD in Medicare
prnewswire.com • 6mo ago 
